Health-related quality of life in primary and secondary adrenal insufficiency

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 14, Issue 6, 2014, Pages 873-888

  Aulinas, Anna ^a   Webb, Susan M ^a,b  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE ENFERMEDADES RARAS CIBERER   (Spain)

Author keywords

Addison's disease; Congenital adrenal hyperplasia; Health related quality of life; Primary adrenal insufficiency; Quality of life; Secondary adrenal insufficiency

Indexed keywords

CORTISONE ACETATE; DEXAMETHASONE; HYDROCORTISONE; PREDNISOLONE; GLUCOCORTICOID;

ADRENAL INSUFFICIENCY; ANDROGEN DEFICIENCY; CIRCADIAN RHYTHM; CLINICAL EVALUATION; CLINICAL FEATURE; CONGENITAL ADRENAL HYPERPLASIA; HORMONE SUBSTITUTION; HUMAN; MORBIDITY; OUTCOME ASSESSMENT; QUALITY OF LIFE; QUESTIONNAIRE; REVIEW; SOCIAL STATUS; ADDISON DISEASE; COST OF ILLNESS; PREDICTIVE VALUE; PSYCHOLOGY; RISK FACTOR; TREATMENT OUTCOME;

ADDISON DISEASE; ADRENAL INSUFFICIENCY; COST OF ILLNESS; GLUCOCORTICOIDS; HORMONE REPLACEMENT THERAPY; HUMANS; PREDICTIVE VALUE OF TESTS; QUALITY OF LIFE; QUESTIONNAIRES; RISK FACTORS; TREATMENT OUTCOME;

EID: 84909961230     PISSN: 14737167     EISSN: 17448379     Source Type: Journal    
DOI: 10.1586/14737167.2014.963559     Document Type: Review

References (83)

1. Bornstein SR. Predisposing factors for adrenal insufficiency. N Engl J Med 2009;360(22):2328-39
2. Grossman A, Johannsson G, Quinkler M, Zelissen P. Perspective on the management of adrenal insufficiency: clinical insights from across Europe. Eur J Endocrinol 2013;169(6):R165-75
3. Charmandari E, Nicolaides NC, Chrousos GP. Adrenal Insufficiency. Lancet 2014;383(9935):2152-67
4. Bergthorsdottir R, Leonsson-Zachrisson M, Odén A, Johannsson G. Premature mortality in patient with Addison's disease: a population-based study. J Clin Endocrinol Metab 2006;91(12):4849-53
5. Mills JL, Schonberger LB, Wysowski DK, et al. Long-term mortality in the United States cohort of pituitary-derived growth hormone recipients. J Pediat 2004;144(4):430-6
6. Rosén T, Bengtsson BA. Premature mortality due to cardiovascular disease in hypopituitarism. Lancet 1990;336(8719):285-8
7. Bates AS, Van't Hoff W, Jones PF, Clayton RN. The effect of hypopituitarism on life expectancy. J Clin Endocrinol Metab 1996;81(3):1169-72
8. Bülow B, Hagmar L, Mikoczy Z, et al. Increased cerebrovascular mortality in patients with hypopituitarism. Clin Endocrinol (Oxf) 1997;46(1):75-81
9. Bensing S, Brandt L, Tabaroj F, et al. Increased death risk and altered cancer incidence pattern in patients with isolated or combined autoimmune primary adrenocortical insufficiency. Clin Endocrinol (Oxf) 2008;69(5):697-704
10. Erichsen MM, Lovas K, Fougner KJ, et al. Normal overall mortality rate in Addison's disease, but young patients are at risk of premature death. Eur J Endocrinol 2009;160(2):233-7
11. Han TS, Krone N, Willis DS, et al. Quality of life in adults with congenital adrenal hyperplasia relates to glucocorticoid treatment, adiposity and insulin resistance: united Kingdom Congenital adrenal Hyperplasia Adult Study Executive (CaHASE). Eur J Endocrinol 2013;168(6):887-93
12. Bleicken B, Hahner S, Ventz M, Quinkler M. Delayed diagnosis of adrenal insufficiency is common: a cross-sectional study in 216 patients. Am J Med Sci 2010;339(6):525-31
13. Filipsson H, Monson JP, Koltowska-Häggström M, et al. The impact of glucocorticoid replacement regiments on metabolic outcome and comorbidity in hypopituitary patients. J Clin Endocrinol Metab 2006;91(10):3954-61
14. Dallman MF, Akana SF, Bhatnagar S, et al. Bottomed out: metabolic significance of the circadian trough in glucocorticoid concentration. Int J Obes 2000;24(Suppl 2):S40-6
15. Lovas D, Gjesdal CG, Christensen M, et al. Glucocorticoid replacement therapy and pharmacogenetics in Addison's disease: effects on bone. Eur J Endocrinol 2009;160(6):993-1002
16. Falhammar H, Filipsson H, Wedell A, et al. Bone mineral density, bone markers, and fractures in adult males with congenital adrenal hyperplasia. Eur J Endocrinol 2013;168(3):331-41
17. Loechner KH, Patel S, Fordham L, McLaughlin JT. Decreased bone mineral density and vertebral compression fractures in a young adult male with 21-hydroxylase deficiency congenital adrenal hyperplasia (CAH): is CAH an unrecognized population at risk for glucocorticoid-induced osteoporosis? J Pediatr Endocrinol Metab 2010;23(1-2):179-87
18. Koetz KR, Ventz M, Diederich S, Quinkler M. Bone mineral density is not significantly reduced in adult patients on low-dose glucocorticoid replacement therapy. J Clin Endocrinol Metab 2012;97(1):85-92
19. Björnsdottir S, Sääf M, Bensing S, et al. Risk of hip fracture in Addison's disease: a population-based cohort study. J Intern Med 2011;270(2):187-95
20. Bornstein SR, Breidert M, Ehrhart-Bornstein M, et al. Plasma catecholamines in patients with Addison's disease. Clin Endocrinol (Oxf) 1995;42(2):215-18
21. Green-Golan L, Yates C, Drinkard B, et al. Patients with classic congenital adrenal hyperplasia have decreased epinephrine reserve and defective glycemic control during prolonged moderate-intensity exercise. J Clin Endocrinol Metab 2007;92(8):3019-24
22. Aulinas A, Casanueva F, Goñi F, et al. Insuficiencia suprarrenal y su tratamiento sustitutivo. Su realidad en España. Endocrinol Nutr 2013;60(3):136-43
23. Lovas K, Husebye ES, Holsten F, Bjorvatn N. Sleep disturbances in patients with Addison's disease. Eur J Endocrinol 2003;148(4):449-56
24. Buckley TM, Schatzberg AF. Review: on the interactions of the hypothalamic-pituitary-adrenal (HPA) axis and sleep: normal HPA axis activity and circadian rhythm, exemplary sleep disorders. J Clin Endocrinol Metab 2006;90(5):3106-14
25. Oksnes M, Björnsdottir S, Isaksson M, et al. Continuous subcutaneous hydrocortisone infusion versus oral hydrocortisone replacement for treatment of Addison's disease: a randomized clinical trial. J Clin Endocrinol Metab 2014;99(5):1665-74
26. García-Borreguero D, Wehr TA, Larrosa O, et al. Glucocorticoid replacement is permissive for rapid eye movement sleep and sleep consolidation in patients with adrenal insufficiency. J Clin Endocrinol Metab 2000;85(11):4201-6
27. Vgontzas AN, Bixler EO, Lin HM, et al. Chronic insomnia is associated with nyctohemeral activation of the hypothalamic-pituitary-adrenal axis: clinical implications. J Clin Endocrinol Metab 2001;86(8):3787-94
28. Harbeck B, Kropp P, Mönig H. Effects of short-term nocturnal cortisol replacement on cognitive function and quality of life in patients with primary or secondary adrenal insufficiency: a pilot study. Appl Psychophysiol Biofeedback 2009;34(2):113-19
29. Thomsen AF, Kvist TK, Andersen PK, Kessing LV. The risk of affective disorders in patients with adrenocortical insufficiency. Psychoneuroendocrinology 2006;31(5):614-22
30. Warmuz-Stangierska I, Baszko-Blaszyk D, Sowiński J. Emotions and features of temperament in patients with Addison's disease. Endocrynol Pol 2010;61(1):90-2
31. Anglin RE, Rosebush PI, Mazurek MF. The neuropsychiatric profile of Addison's disease: revisiting a forgotten phenomenon. J Neuropsychiatry Clin Neurosci 2006;18(4):450-9
32. Tiemensma J, Andela CD, Kaptein AA, et al. Psychological morbidity and impaired quality of life in patients with stable treatment for primary adrenal insufficiency: cross-sectional study and review of the literature. Eur J Endocrinol 2014;171(2):141-82
33. Meyer-Bahlburg HF. Brain development and cognitive, psychosocial, and psychiatric functioning in classical 21-hydroxylase deficiency. Endocr Dev 2011;20:88-95
34. Falhammar H, Butwicka A, Landén M, et al. Increased psychiatric morbidity in men with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J Clin Endocrinol Metab 2014;99(3):E554-60
35. Johannsson G, Burman P, Wirén L, et al. Low dose dehydroepiandrosterone affects behavior in hypopituitary androgen-deficient women: a placebo-controlled trial. J Clin Endocrinol Metab 2002;87(5):2046-52
36. Alkatib AA, Cosma M, Elamin MB, et al. A systematic Review and meta-analysis of randomized placebo-controlled trials of DHEA treatment effects on quality of life in women with adrenal insufficiency. J Clin Endocrinol Metab 2009;94(10):3676-81
37. McHenry CM, Bell PM, Hunter SJ, et al. Effects of dehydroepiandrosterone sulphate (DHEAS) replacement on insulin action and quality of life in hypopituitary females: a double-blind, placebo-controlled study. Clin Endocrinol (Oxf) 2012;77(3):423-9
38. van Thiel SW, Romijn JA, Pereira AM, et al. Effects of dehydroepiandrostenedione, superimposed on growth hormone substitution, on quality of life and insulin-like growth factor I in patients with secondary adrenal insufficiency: a randomized, placebo-controlled, cross-over trial. J Clin Endocrinol Metab 2005;90(6):3295-303
39. Brooke AM, Kalingag LA, Miraki-Moud F, et al. Dehydroepiandrosterone improves psychological well-being in male and female hypopituitary patients on maintenance growth hormone replacement. J Clin Endocrinol Metab 2006;91(10):3773-9
40. Grossman AB. The diagnosis and management of central hypoadrenalism. J Clin Endocrinol Metab 2010;95(11):4855-63
41. Erichsen MM, Husebye ES, Michelsen TM, et al. Sexuality and fertility in women with Addison's disease. J Clin Endocrinol Metab 2012;95(9):4354-60
42. Forss M, Batcheller G, Skrtic S, Johannsson G. Current practice of glucocorticoid replacement therapy and patient-perceived health outcomes in adrenal insufficiency - a worldwide patient survey. BMC Endocr Disord 2012;12:8
43. Hahner S, Loeffler M, Fassnacht M, et al. Impaired subjective health status in 256 patients with adrenal insufficiency on standard therapy based on cross-sectional analysis. J Clin Endocrinol Metab 2007;92(10):3912-22
44. Strandqvist A, Falhammar H, Lichtenstein P, et al. Suboptimal psychosocial outcomes in patients with congenital adrenal hyperplasia: epidemiological studies in a nonbiased national cohort in Sweden. J Clin Endocrinol Metab 2014;99(4):1425-32
45. Lovas K, Harvard Loge J, Husebye ES. Subjective health status in Norwegian patients with Addison's disease. Clin Endocrinol (Oxf) 2002;56(5):581-8
46. Debono M, Ross RJ, Newell-Price J. Inadequacies of glucocorticoid replacement and improvements by physiological circadian therapy. Eur J Endocrinol 2009;160(5):719-29
47. Arlt W, Rosenthal C, Hahner S, Allolio B. Quality of glucocorticoid replacement in adrenal insufficiency: clinical assessment vs. timed serum cortisol measurements. Clin Endocrinol (Oxf) 2006;64(4):384-9
48. Smans L, Lentjes E, Hermus A, Zelissen P. Salivary cortisol day curves in assessing glucocorticoid replacement therapy in Addison's disease. Hormones (Athens) 2013;12(1):93-100
49. Bleicken B, Hahner S, Loeffler M, et al. Impaired subjective health status in chronic adrenal insufficiency: impact of different glucocorticoid replacement regimens. Eur J Endocrinol 2008;159(6):811-17
50. Kluger N, Matikainen N, Sintonen H, et al. Impaired health-related quality of life in Addison's disease - Impact of replacement therapy, co-morbidities and socioeconomic factors. Clin Endocrinol (Oxf) 2014. [Epub ahead of print] doi:10.1111/cen.12484
51. Bleicken B, Hahner S, Loeffler M, et al. Influence of hydrocortisone dosage scheme on health-related quality of life in patients with adrenal insufficiency. Clin Endocrinol (Oxf) 2010;72(3):297-304
52. Alonso N, Granada ML, Lucas A, et al. Evaluation of two replacement regimens in primary adrenal insufficiency patients. Effect on clinical symptoms, health-related quality of life and biochemical parameters. J Endocrinol Invest 2004;27(5):449-54
53. Benson S, Neumann P, Unger N, et al. Effects of standard glucocorticoid replacement therapies on subjective well-being: a randomized, doubled-blind, crossover study in patients with secondary adrenal insufficiency. Eur J Endocrinol 2012;167(5):679-85
54. Ekman B, Bachrach-Lindström M, Lindström T, et al. A randomized, double-blink, crossover study comparing two-and four-dose hydrocortisone regimen with regard to quality of life, cortisol and ACTH profiles in patients with primary adrenal insufficiency. Clin Endocrinol (Oxf) 2012;77(1):18-25
55. Lovas K, Curran S, Oksnes M, et al. Development of a disease-specific quality of life questionnaire in Addison's disease. J Clin Endocrinol Metab 2010;95(2):545-51
56. Badia X, Valassi E, Roset M, Webb SM. Disease-specific quality of life evaluation and its determinants in Cushing's syndrome: what have we learnt? Pituitary 2014;17(2):187-95
57. Webb SM, Badia X, Barahona MJ, et al. Evaluation of health-related quality of life in patients with Cushing's syndrome with a new questionnaire. Eur J Endocrinol 2008;158(5):623-30
58. Øksnes M, Bensing S, Hultin AL, et al. Quality of life in European patients with Addison's disease: validity of the disease-specific questionnaires AddiQoL. J Clin Endocrinol Metab 2012;97(2):568-76
59. Grossman AB. The diagnosis and management of central hypoadrenalism. J Clin Endocrinol Metab 2010;95(11):4855-63
60. Simon N, Castinetti F, Ouliac F, et al. Pharmacokinetic evidence for suboptimal treatment of adrenal insufficiency with currently available hydrocortisone tablets. Clin Pharmacokinet 2010;49(7):455-63
61. Johannsson G, Nilsson AG, Bergthorsdottir R, et al. Improved Cortisol Exposure-Time Profile and Outcome in Patients with Adrenal Insufficiency: a Prospective Randomized Trial of a Novel Hydrocortisone Dual-Release Formulation. J Clin Endocrinol Metab 2012;97(2):473-81
62. Debono M, Ross RJ. What is the best approach to tailoring hydrocortisone dose to meet patient needs in 2012. Clin Endocrinol (Oxf) 2013;78(5):659-64
63. Newell-Price J, Whiteman M, Rostami-Hodjegan A, et al. Modified-release hydrocortisone for circadian therapy: a proof-of-principle study in dexamethasone-suppressed normal volunteers. Clin Endocrinol (Oxf) 2008;68(1):130-5
64. Lovas K, Husebye E. Continuous subcutaneous hydrocortisone infusion in Addison's disease. Eur J Endocrinol 2007;157(1):109-12
65. Oksnes M, Björnsdottir S, Isaksson M, et al. Continuous subcutaneous hydrocortisone infusion versus oral hydrocortisone replacement for treatment of Addison's disease: a randomized clinical trial. J Clin Endocrinol Metab 2014;99(5):1665-74
66. Speiser PW, Azziz R, Baskin LS, et al. Congenital adrenal hyperplasia due to steroid 21-hydrosylase deficiency: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2010;95(9):4133-60
67. Reisch N, Hahner S, Bleicken B, et al. Quality of life is less impaired in adults with congenital adrenal hyperplasia because of 21-hydroxylase deficiency than in patients with primary adrenal insufficiency. Clin Endocrinol (Oxf) 2011;74(2):166-73
68. Charmandari E, Eisenhofer G, Mehlinger SL, et al. Adrenomedullary function may predict phenotype and genotype in classic 21-hydroxylase deficiency. J Clin Endocrinol Metab 2012;87(7):3031-7
69. Nermoen I, Husebye ES, Svartberg J, Lovas K. Subjective health status in men and women with congenital adrenal hyperplasia: a population-based survey in Norway. Eur J Endocrinol 2010;163(3):453-9
70. Gilban DLS, Alves Junior P, Beserra I. Health related quality of life of children and adolescents with congenital adrenal hyperplasia in Brazil. Health Qual Life Outcomes 2014;12(1):107. [Epub ahead of print]
71. Sanches SA, Wiegers TA, Otten BJ, Claahsen-van der Grinten HL. Physical, social and societal functioning of children with congenital adrenal hyperplasia (CAH) and their parents, in a Dutch population. Int J Pediatr Endocrinol 2012;2(1):2
72. Frisén L, Nordenström A, Falhammar H, et al. Gender role behavior, sexuality, and psychosocial adaptation in women with congenital adrenal hyperplasia due to CYP21A2 deficiency. J Clin Endocrinol Metab 2009;94(9):3432-9
73. Jääskeläinen Voutilainen R. Long-term outcome of classical 21-hydroxylase deficiency: diagnosis, complications and quality of life. Acta Paediatr 2000;89(2):183-7
74. Tanaka T, Tai S, Morisake Y, et al. Evaluation of quality of life in children with GH deficiency and idiopathic short stature using the child behavior checklist. Clin Pediatr Endocrinol 2009;18(1):15-22
75. Han TS, Stimson RH, Rees DA, et al. Glucocorticoid treatment regimen and health outcomes in adults with congenital adrenal hyperplasia. Clin Endocrinol (Oxf) 2013;78(2):197-203
76. Falhammar H, Nyström HF, Thorén M. Quality of life, social situation, and sexual satisfaction, in adult males with congenital adrenal hyperplasia. Endocrine 2014. [Epub ahead of print]
77. Arlt W, Willis DS, Wild SH, et al. Health status of adults with congenital adrenal hyperplasia: a cohort study of 203 patients. J Clin Endocrinol Metab 2010;95(11):5110-21
78. Bleicken B, Ventz M, Hinz A, Quinkler M. Improvement of health-related quality of life in adult women with 21-hydroxylase deficiency over seven-year period. Endocr J 2012;59(10):931-9
79. Norenskjöld A, Holmdahl G, Frisén L, et al. Type of mutation and surgical procedure affect long-term quality of life for women with congenital adrenal hyperplasia. J Clin Endocrinol Metab 2008;93(2):380-6
80. Shimon I, Kaiserman I, Sack J. Home monitoring of 17 alpha-hydroxyprogesterone levels by filter paper blood spots in patients with 21-hydroxylase deficiency. Horm Res 1995;44(6):247-52
81. Santos CM, Abad LR, Cua SC, Domingo CF. Monitoring congenital adrenal hyperplasia using blood spot 17-hydroxyprogesterone assay. Southeast Asian J Trop Med Public Health 2003;34(Suppl 3):174-8
82. Debono M, Ghodabi C, Rostami-Hodjegan A, et al. Modified-release hydrocortisone to provide circadian cortisol profiles. J Clin Endocrinol Metab 2009;94(5):1548-54
83. Bryan SM, Honour JW, Hinkmarsh PC. Management of altered hydrocortisone pharmacokinetics in a boy with congenital adrenal hyperplasia using a continuous subcutaneous hydrocortisone infusion. J Clin Endocrinol Metab 2009;94(9):3477-80